» Articles » PMID: 36626512

Prognostic Influence for Hilar Cholangiocarcinoma and Comparisons of Prognostic Values of Mayo Staging and TNM Staging Systems

Abstract

The study was designed to discuss the effect of stratification factors in the Mayo staging on the prognosis of hilar cholangiocarcinoma (HCCA) patients, and to evaluate the predictive value of the Mayo staging on the prognosis. The Kaplan-Meier survival curve and Log-rank test were used to perform univariate analysis on each index and obtain statistically significant influencing factors. The Kaplan-Meier survival curve and Log-rank test were used to analyze the correlation between the two staging systems and the survival period. The receiver operating characteristic (ROC) curves were used for each single staging system trend analysis, and comparison of their curve area to determine prognosis prediction ability for patients with HCCA. According to Kaplan-Meier survival curve changes and Log-rank test results, it was found that both staging systems were correlated with the survival time of the patients (P < .001). Through a pairwise comparison within the stages, it was found that the heterogeneity between the stages within the Mayo staging is very good, which was better than the TNM staging. A single trend analysis of the prognostic assessment capabilities of the two systems found that the area under the ROC curve of Mayo staging system (AUC = 0.587) was the largest and better than the TNM staging system (AUC = 0.501). Mayo staging can be used for preoperative patient prognosis assessment which can provide better stratification ability based on a single-center small sample study, and the predictive value is better than TNM staging.

Citing Articles

CT Texture Analysis of Perihilar Cholangiocarcinoma-Associations With Tumor Grading, Tumor Markers and Clinical Outcome.

Leonhardi J, Sabanov A, Hohn A, Sucher R, Seehofer D, Mehdorn M Cancer Rep (Hoboken). 2024; 7(9):e2132.

PMID: 39307946 PMC: 11417006. DOI: 10.1002/cnr2.2132.

References
1.
DeOliveira M, Schulick R, Nimura Y, Rosen C, Gores G, Neuhaus P . New staging system and a registry for perihilar cholangiocarcinoma. Hepatology. 2011; 53(4):1363-71. DOI: 10.1002/hep.24227. View

2.
Tan E, Taner T, Heimbach J, Gores G, Rosen C . Liver Transplantation for Peri-hilar Cholangiocarcinoma. J Gastrointest Surg. 2020; 24(11):2679-2685. DOI: 10.1007/s11605-020-04721-4. View

3.
Sapisochin G, de Sevilla E, Echeverri J, Charco R . Liver transplantation for cholangiocarcinoma: Current status and new insights. World J Hepatol. 2015; 7(22):2396-403. PMC: 4598610. DOI: 10.4254/wjh.v7.i22.2396. View

4.
Azad A, Rosen C, Taner T, Heimbach J, Gores G . Selected Patients with Unresectable Perihilar Cholangiocarcinoma (pCCA) Derive Long-Term Benefit from Liver Transplantation. Cancers (Basel). 2020; 12(11). PMC: 7693604. DOI: 10.3390/cancers12113157. View

5.
Heimbach J, Gores G, Haddock M, Alberts S, Pedersen R, Kremers W . Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation. 2007; 82(12):1703-7. DOI: 10.1097/01.tp.0000253551.43583.d1. View